281
Participants
Start Date
July 5, 2020
Primary Completion Date
July 19, 2024
Study Completion Date
July 19, 2024
Nucleos(t)ide (NUC)
Nucleos(t)ide (NUC) will be administered orally
CpAM (RO7049389)
CpAM (RO7049389) will be administered orally
TLR7 (RO7020531)
TLR7 (RO7020531) will be administered orally
siRNA (RO7445482)
siRNA (RO7445482) will be administered subcutaneously
PEG-IFN
PEG-IFN will be administered subcutaneously
PD-L1 LNA (RO7191863)
PD-L1 LNA (RO7191863) will be administered subcutaneously
Changhua Christian Hospital, Chang-hua
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Auckland Clinical Studies Limited, Auckland
Tokuda Hospital Sofia, Sofia
"University Multiprofile Hospital For Active Treatment Sveti Ivan Rilski EAD", Sofia
National Taiwan University Hospital, Taipei
HIVNAT, Bangkok
Siriraj Hospital, Bangkok
Hospital Alvaro Cunqueiro, Vigo
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai
Hopital Beaujon, Clichy
Beijing Friendship Hospital, Beijing
The First Hospital of Jilin University, Changchun
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai
Huashan Hospital, Fudan University, Shanghai
Spitalul Clinic Judetean de Urgenta Cluj Napoca, Cluj-Napoca
Nanfang Hospital, Southern Medical University, Guangzhou
West China Hospital, Sichuan University, Chengdu
Hospital San Juan de Dios La Serena, La Serena
University of Calgary, Calgary
Uni of Alberta Hospital, Edmonton
Toronto Liver Centre, Toronto
Queen Mary Hospital, Hong Kong
Middlemore Clinical Trials, Auckland
Seoul National University College of Medicine, Liver Research Institute, Seoul
Chuncheon Sacred Heart Hospital, Gangwon-Do
Asan Medical Center / Clinical Trial Center, Seoul
SMG-SNU Boramae Medical Center, Seoul
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
National Cheng Kung Univ Hosp, Tainan City
King College Hospital NHS Foundation Trust, London
Hoffmann-La Roche
INDUSTRY